bentamapimod

Bentamapimod is a novel, orally active small molecule inhibitor of c-Jun N-terminal kinase (JNK), with potent activity against JNK1, JNK2, and JNK3. It was developed as a potential therapeutic for diseases involving immune dysregulation and inflammation. Bentamapimod has been investigated primarily for the treatment of endometriosis, where it demonstrated the ability to induce regression of endometriotic lesions in preclinical rodent models by interrupting immune pathways and reducing inflammatory cytokine secretion. The drug also showed selective cytotoxic activity against cancer cells _in vitro_ and was previously explored for neurological diseases such as multiple sclerosis. Its mechanism involves inhibition of the JNK mitogen-activated protein kinase pathway, which plays a key role in cellular stress responses and inflammation[1][5][6][8].

Other names

bentamapimod